SynAct Pharma AB (SYNACT.ST) Research

SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently being developed for the treatment of both rheumatoid arthritis and idiopathic membranous glomerulonephritis. Additionally, SynAct Pharma maintains a collaborative research initiative with the University of Örebro, focusing on the mitigation of inflammation in vascular diseases. Established in 2012, the firm's corporate headquarters are situated in Lund, Sweden.

Market snapshot

Symbol
SYNACT.ST
Price
$11.66
Day change
+9.38%
Market cap
$619.3M
P/E ratio
-5.45x
52-week range
7.05-25.3
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Cantargia AB (publ) (CANTA.ST)
  • C-Rad AB (publ) (CRAD-B.ST)
  • Diamyd Medical AB (publ) (DMYD-B.ST)
  • Genovis AB (publ.) (GENO.ST)
  • Infant Bacterial Therapeutics AB (publ) (IBT-B.ST)
  • I-Tech AB (ITECH.ST)
  • Oncopeptides AB (publ) (ONCO.ST)
  • Orexo AB (publ) (ORX.ST)

Open SynAct Pharma AB (SYNACT.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.